Structure Therapeutics price target lowered to $90 from $92 at Guggenheim

Guggenheim lowered the firm’s price target on Structure Therapeutics (GPCR) to $90 from $92 and keeps a Buy rating on the shares after the company reiterated that top-line data from the Phase 2b ACCESS and ACCESS II studies for oral small molecule GLP1RA aleniglipron are on track for concurrent year-end 2025 readouts. The firm continues to recommend that investors build a position in advance of the ACCESS/ACCESS II readouts given what it sees as “a mismatched valuation.”